Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 06/28 10:00:10 pm
55.58 USD   +0.49%
06/28 Imperial Innovations Says Storm Therapeutics Raises New Funds
06/27 MERCK : Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab)..
06/25 MERCK : OBS Pakistan acquiring Merck Serono
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2012 | 03:17pm CEST
   By Tess Stynes 
 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
06/28 Imperial Innovations Says Storm Therapeutics Raises New Funds
06/27 MERCK : Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Tre..
06/25 MERCK : OBS Pakistan acquiring Merck Serono
06/24 MERCK : to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 2..
06/23 MERCK : Robert F. Majors Jr.
06/22 Roche CEO 'sleeps better' as risk to drugmaker's growth recedes
06/20 MERCK : Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase..
06/17 MERCK : Covered Call reports for Gilead Sciences, Activision Blizzard, General E..
06/16 MERCK : New Hydrochloric Acid Findings from Merck & Company Described (Gasometri..
06/16DJMARKET SNAPSHOT : Stocks Snap 5-day Losing Streak; Dow Reverses Triple-digit Los..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials